Trial
NCT02972658
A Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease Dementia
Phase IIITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
AstraZeneca
Collaborators
Eli Lilly and Company
Condition
Alzheimer's Disease
Intervention
Lanabecestat
Why stopped
As the feeder study (AZES) was stopped for futility after an independent assessment, this trial was also stopped.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2019-12-03